Role of Body Composition in Patients with Resectable Pancreatic Cancer
Authors:
- Annarita PecchiAPAnnarita Pecchi
- Filippo ValorianiFVFilippo Valoriani
- Riccardo Cuoghi CostantiniRCRiccardo Cuoghi Costantini
- Denise SqueccoDSDenise Squecco
- Andrea SpallanzaniASAndrea Spallanzani
- Roberto D’amicoRDRoberto D’amico
- Massimo DominiciMDMassimo Dominici
- Fabrizio Di BenedettoFBFabrizio Di Benedetto
- Pietro TorricelliPTPietro Torricelli
- Renata MenozziRMRenata Menozzi
Open Access
Abstract
This study investigates the role of body composition parameters in patients with pancreatic cancer undergoing surgical treatment. The research involved 88 patients diagnosed with pancreatic cancer who underwent surgery at the Modena Cancer Center between June 2015 and October 2023. Body composition parameters were obtained from CT scans performed before and after surgery. The percentage of sarcopenic patients at the time of diagnosis of pancreatic cancer is 56.82%. Of the patients who died between the first and second CT evaluated, 58% were sarcopenic, thus confirming the role of sarcopenia on outcome. The study found that all body composition parameters (TAMA, SMI, VFI, and SFI) demonstrated a trend towards reduction between two examinations, indicating an overall depletion in muscle and adipose tissue. We then evaluated the relationships between fat-related parameters (VFI, SFI and VSR) and survival outcomes: overall survival and progression-free survival. Cox univariate regression model show significant parameter related to outcomes was adipose tissue, specifically VFI. The study found that higher VFI levels were associated with greater survival rates. This research holds promise for advancing our understanding of the link between body composition and the prognosis of pancreatic cancer patients.Keywords
This publication has 51 references indexed in Scilit:
- Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancerJournal of Cachexia, Sarcopenia and Muscle, 2024
- Body composition parameters predict survival in pancreatic cancer—A retrospective multicenter analysisUnited European Gastroenterology Journal, 2023
- Developments in pancreatic cancer surgeryUpdates in Surgery, 2023
- Sarcopenia ≠ low muscle massEuropean Geriatric Medicine, 2023
- Sarcopenia: how to measure, when and whyLa radiologia medica, 2022
- Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapyClinical Nutrition ESPEN, 2021
- Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancerCancer Medicine, 2021
- Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort studyCancer Medicine, 2020
- Imaging of sarcopenia: old evidence and new insightsEuropean Radiology, 2019
- Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgeryBritish Journal of Surgery, 2016